FR18C1020I2 - Sels pharmaceutiquement acceptables de 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide - Google Patents

Sels pharmaceutiquement acceptables de 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide

Info

Publication number
FR18C1020I2
FR18C1020I2 FR18C1020C FR18C1020C FR18C1020I2 FR 18C1020 I2 FR18C1020 I2 FR 18C1020I2 FR 18C1020 C FR18C1020 C FR 18C1020C FR 18C1020 C FR18C1020 C FR 18C1020C FR 18C1020 I2 FR18C1020 I2 FR 18C1020I2
Authority
FR
France
Prior art keywords
indazole
piperidin
carboxamide
phenyl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR18C1020C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon Pharma UK Ltd
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme Ltd
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40404013&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR18C1020(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp and Dohme Ltd, Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme Ltd
Publication of FR18C1020I1 publication Critical patent/FR18C1020I1/fr
Application granted granted Critical
Publication of FR18C1020I2 publication Critical patent/FR18C1020I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • AIDS & HIV (AREA)
FR18C1020C 2008-01-08 2018-05-14 Sels pharmaceutiquement acceptables de 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide Active FR18C1020I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1033308P 2008-01-08 2008-01-08
PCT/GB2009/000041 WO2009087381A1 (en) 2008-01-08 2009-01-08 Pharmaceutically acceptable salts of 2-{4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide

Publications (2)

Publication Number Publication Date
FR18C1020I1 FR18C1020I1 (enExample) 2018-07-13
FR18C1020I2 true FR18C1020I2 (fr) 2019-06-07

Family

ID=40404013

Family Applications (1)

Application Number Title Priority Date Filing Date
FR18C1020C Active FR18C1020I2 (fr) 2008-01-08 2018-05-14 Sels pharmaceutiquement acceptables de 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide

Country Status (16)

Country Link
US (1) US8436185B2 (enExample)
EP (1) EP2240466B1 (enExample)
JP (1) JP5989965B2 (enExample)
KR (1) KR101653548B1 (enExample)
CN (2) CN106008460B (enExample)
AU (1) AU2009203598B2 (enExample)
BR (1) BRPI0906020A2 (enExample)
CA (1) CA2711491C (enExample)
ES (1) ES2548131T3 (enExample)
FR (1) FR18C1020I2 (enExample)
IL (1) IL206201A (enExample)
MX (1) MX337421B (enExample)
NL (1) NL300938I2 (enExample)
NZ (1) NZ586675A (enExample)
WO (1) WO2009087381A1 (enExample)
ZA (1) ZA201003902B (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2740746A1 (en) 2008-10-14 2010-04-22 Ning Xi Compounds comprising a spiro-ring and and methods of use
EP2408300B1 (en) 2009-03-21 2016-05-11 Sunshine Lake Pharma Co., Ltd. Amino ester derivatives, salts thereof and methods of use
DK3150610T3 (da) 2010-02-12 2019-11-04 Pfizer Salte og polymorfer af 8-fluor-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-on
US9580407B2 (en) 2012-12-07 2017-02-28 Merck Sharp & Dohme Corp. Regioselective N-2 arylation of indazoles
PL3157566T3 (pl) 2014-06-17 2019-10-31 Vertex Pharma Metoda leczenia nowotworu przy użyciu kombinacji inhibitorów chk1 i atr
EP3277321B1 (en) 2015-04-01 2024-08-14 AnaptysBio, Inc. Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
DK3358347T3 (da) * 2015-09-30 2020-11-30 Univ Tohoku Markør til bestemmelse af diabetisk nefropati
KR102678021B1 (ko) 2015-09-30 2024-06-26 버텍스 파마슈티칼스 인코포레이티드 Dna 손상제와 병용되는, atr 저해제를 포함하는 암 치료용 약제학적 조성물
FI3478286T3 (fi) 2016-06-29 2024-03-14 Tesaro Inc Menetelmiä munasarjasyövän hoitamiseksi
CN119606965A (zh) 2016-07-29 2025-03-14 詹森药业有限公司 治疗前列腺癌的方法
CN107663190B (zh) * 2016-07-29 2020-06-09 钟桂发 一种尼拉帕尼及其中间体的制备方法以及中间体化合物
CN106432057A (zh) * 2016-09-17 2017-02-22 青岛云天生物技术有限公司 一种制备(3s)‑3‑(4‑氨基苯基)哌啶‑1‑甲酸叔丁酯的方法
SG11201903867YA (en) 2016-11-01 2019-05-30 Anaptysbio Inc Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
EP3666794A1 (en) 2016-11-01 2020-06-17 AnaptysBio, Inc. Antibodies directed against programmed death- 1 (pd-1)
WO2018122168A1 (en) 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinations of bub1 kinase and parp inhibitors
JP7118073B2 (ja) 2017-01-09 2022-08-15 テサロ， インコーポレイテッド 抗ｔｉｍ－３抗体を用いてがんを処置する方法
EP3565844B8 (en) 2017-01-09 2023-04-12 Tesaro, Inc. Methods of treating cancer with anti-pd-1 antibodies
BR112019020191A2 (pt) * 2017-03-27 2020-04-22 Tesaro Inc formulações de niraparib
EA201992177A1 (ru) * 2017-03-27 2020-02-25 Тесаро, Инк. Композиции на основе нирапариба
WO2018187187A1 (en) * 2017-04-04 2018-10-11 Combiphos Catalysts, Inc. Deuterated (s)-2-(4-(piperidin-3-yl)phenyl)-2h-indazole-7-carboxamide
EA201992430A1 (ru) 2017-04-13 2020-02-28 Янссен Фармацевтика Нв Комбинированная терапия рака предстательной железы
CN110753684A (zh) 2017-04-24 2020-02-04 特沙诺有限公司 尼拉帕利的制造方法
SG11201909395TA (en) 2017-04-27 2019-11-28 Tesaro Inc Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
TW202444417A (zh) 2017-05-09 2024-11-16 美商提薩羅有限公司 治療癌症的組合療法
EP3624850A1 (en) 2017-05-18 2020-03-25 Tesaro, Inc. Combination therapies for treating cancer
CN108530425A (zh) * 2017-05-27 2018-09-14 广州科锐特生物科技有限公司 一种尼拉帕尼对甲苯磺酸盐水合物晶型及其制备方法
CN109081828B (zh) * 2017-06-14 2021-03-26 上海时莱生物技术有限公司 聚(adp-核糖)聚合酶抑制剂、制备方法及用途
EP3668857B1 (en) 2017-08-14 2023-07-05 Teva Pharmaceuticals International GmbH Processes for the preparation of niraparib and intermediates thereof
EP3682236A1 (en) * 2017-09-13 2020-07-22 B.R.A.H.M.S GmbH Proadrenomedullin as indicator for renal replacement therapy in critically ill patients
EP4027145A1 (en) * 2017-09-13 2022-07-13 B.R.A.H.M.S GmbH Pro-adm for therapy monitoring of intensive care unit patients
EP3682246A1 (en) * 2017-09-13 2020-07-22 B.R.A.H.M.S GmbH Method for guidance of fluid therapy based on proadrenomedullin
AU2018341479B2 (en) * 2017-09-26 2022-02-17 Tesaro, Inc. Niraparib formulations
KR20200086664A (ko) 2017-09-30 2020-07-17 테사로, 인코포레이티드 암을 치료하기 위한 조합 요법
MA50618A (fr) * 2017-10-06 2020-08-12 Tesaro Inc Polyrhérapies et leurs utilisations
CA3087060A1 (en) 2017-12-27 2019-07-04 Tesaro, Inc. Methods of treating cancer
EP3749352A1 (en) 2018-02-05 2020-12-16 Tesaro Inc. Pediatric niraparib formulations and pediatric treatment methods
TWI852940B (zh) 2018-09-04 2024-08-21 美商泰沙羅公司 治療癌症之方法
CN118994103A (zh) * 2018-10-03 2024-11-22 特沙诺有限公司 尼拉帕利盐
US20210347758A1 (en) * 2018-10-03 2021-11-11 Tesaro, Inc. Crystalline Forms of Niraparib Freebase
WO2020072860A1 (en) 2018-10-05 2020-04-09 Johnson Matthey Public Limited Company Niraparib solid state form
EP3966782A2 (en) 2019-05-06 2022-03-16 Tesaro, Inc. Methods for characterizing and treating a cancer type using cancer images
CN110407704B (zh) * 2019-08-19 2022-05-17 常州沃腾化工科技有限公司 一种3-甲酰基-2-硝基苯甲酸甲酯的合成方法
CN114391013B (zh) 2019-09-24 2024-01-26 上海美悦生物科技发展有限公司 一种irak抑制剂及其制备方法和用途
AU2021269115A1 (en) 2020-05-08 2023-01-19 Janssen Pharmaceutica Nv Treatment of prostate cancer with a combination of abiraterone acetate and niraparib
EP4373491A1 (en) 2021-07-19 2024-05-29 JANSSEN Pharmaceutica NV Treatment of metastatic castration-resistant prostate cancer with niraparib
MX2024009626A (es) 2022-02-04 2024-08-09 Janssen Pharmaceutica Nv Niraparib y acetato de abiraterona mas prednisona para mejorar los resultados clinicos en pacientes con cancer de prostata resistente a la castracion metastasico y alteraciones del hrr.
US20250352534A1 (en) 2022-02-15 2025-11-20 Tesaro, Inc. Use of Niraparib for the Treatment of Brain Cancer
EP4712976A1 (en) 2023-05-17 2026-03-25 Tesaro, Inc. Novel use of an inhibior of the a poly-adp ribose polymerase (parp) in the treatment of cancer
WO2025027138A1 (en) 2023-08-02 2025-02-06 Janssen Pharmaceutica Nv Combination of niraparib and abiraterone for use in the treatment of metastatic castration-resistant prostate cancer
CN117843713A (zh) * 2023-12-18 2024-04-09 上海亲合力生物医药科技股份有限公司 基于肿瘤微环境激活的激酶抑制剂、组合物及应用
CN119707921B (zh) * 2024-12-19 2026-03-03 四川轻化工大学 一种尼拉帕尼的合成方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
AT401651B (de) * 1994-06-14 1996-11-25 Biochemie Gmbh 7-(2-(2-aminothiazol-4-yl)-2-(z)- hydroximinoacetamido)-3-n,n- dimethylcarbamoyloxymethyl-3-cephem-4-
PT841924E (pt) 1995-08-02 2003-02-28 Univ Newcastle Ventures Ltd Compostos de benzimidazolo
WO1999059973A1 (en) 1998-05-15 1999-11-25 Guilford Pharmaceuticals Inc. Carboxamide compounds, compositions, and methods for inhibiting parp activity
IL142760A (en) 1998-10-30 2005-12-18 Lonza Ag Method for producing 4-Ä(2',5'-diamino-6'- halopyrimidine-4' -yl) aminoÜ-cyclopent -2- enyl-methanols
EP1391457B1 (de) 1998-11-03 2013-12-25 AbbVie Deutschland GmbH & Co KG Substituierte 2-Phenylbenzimidazole und deren Verwendung als PARP Inhibitoren
AU755694B2 (en) 1998-11-17 2002-12-19 Basf Aktiengesellschaft 2-phenylbenzimidazoles and 2-phenylindoles, and production and use thereof
USRE39608E1 (en) 1998-11-27 2007-05-01 Abbott Gmbh & Co. Kg Substituted benzimidazoles and their use as PARP inhibitors
DE19918211A1 (de) * 1999-04-22 2000-10-26 Basf Ag Cycloalkylsubstituierte Benzimidazole, deren Herstellung und Anwendung
DE19920936A1 (de) * 1999-05-07 2000-11-09 Basf Ag Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
WO2001021615A1 (fr) 1999-09-17 2001-03-29 Yamanouchi Pharmaceutical Co., Ltd. Dérivés de benzimidazole
US6508365B1 (en) * 1999-12-28 2003-01-21 Pitney Bowes Inc. Method of removing mail from a mailstream using an incoming mail sorting apparatus
US7041675B2 (en) * 2000-02-01 2006-05-09 Abbott Gmbh & Co. Kg Heterocyclic compounds and their use as PARP inhibitors
DE10022925A1 (de) * 2000-05-11 2001-11-15 Basf Ag Substituierte Indole als PARP-Inhibitoren
JPWO2002068407A1 (ja) 2001-02-28 2004-06-24 山之内製薬株式会社 ベンゾイミダゾール化合物
WO2003007959A1 (en) 2001-07-16 2003-01-30 Fujisawa Pharmaceutical Co., Ltd. Quinoxaline derivatives which have parp inhibitory action
WO2003062234A1 (en) 2002-01-23 2003-07-31 Yamanouchi Pharmaceutical Co., Ltd. Quinoxaline compounds
US20040034078A1 (en) 2002-06-14 2004-02-19 Agouron Pharmaceuticals, Inc. Benzimidazole inhibitors of poly(ADP-ribosyl) polymerase
DE10228103A1 (de) 2002-06-24 2004-01-15 Bayer Cropscience Ag Fungizide Wirkstoffkombinationen
AU2003252315A1 (en) 2002-08-09 2004-02-25 Kyorin Pharmaceutical Co., Ltd. 4-substituted-quinoline-8-carboxylic amide derivatives and pharmacologically acceptable addition salts thereof
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
KR20060037391A (ko) * 2003-07-21 2006-05-03 스미스클라인 비참 코포레이션 (2Ｓ,4Ｓ)-4-플루오로-1-[4-플루오로-베타-(4-플루오로페닐)-Ｌ-페닐알라닐]-2-피롤리딘카르보니트릴 ｐ-톨루엔설폰산염 및 이의 무수 결정 형태
WO2005047290A2 (en) * 2003-11-11 2005-05-26 Cellular Genomics Inc. Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors
GB0327740D0 (en) * 2003-11-28 2003-12-31 Glaxo Group Ltd Novel compounds
US7544707B2 (en) 2003-12-22 2009-06-09 Eli Lilly And Company Bicyclic derivatives as PPAR modulators
PL1794163T3 (pl) 2004-09-22 2010-06-30 Pfizer Sposób wytwarzania inhibitorów poli(adp-rybozo)polimerazy
DE602005023333D1 (de) * 2004-10-15 2010-10-14 Takeda Pharmaceutical Kinaseinhibitoren
JP3701964B1 (ja) * 2005-03-08 2005-10-05 アステラス製薬株式会社 キヌクリジン誘導体の新規な塩
TWI375673B (en) * 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
WO2006110683A1 (en) 2005-04-11 2006-10-19 Abbott Laboratories 2-substituted-1h-benzimidazole-4-carboxamides are parp inhibitors
EP1895898B1 (en) 2005-06-29 2011-02-16 Compumedics Limited Sensor assembly with conductive bridge
CA2623822C (en) 2005-09-29 2013-11-12 Abbott Laboratories 1h-benzimidazole-4-carboxamides substituted with phenyl at the 2-position are potent parp inhibitors
WO2007059230A2 (en) * 2005-11-15 2007-05-24 Abbott Laboratories Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
US20090275619A1 (en) 2006-04-03 2009-11-05 BOUERES Julia Amide Substituted Indazole and Benzotriazole Derivatives as Poly(ADP-Ribose)Polymerase (PARP) Inhibitors
US20070259937A1 (en) * 2006-05-02 2007-11-08 Giranda Vincent L Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
TW200801513A (en) 2006-06-29 2008-01-01 Fermiscan Australia Pty Ltd Improved process
US7892667B2 (en) * 2006-09-13 2011-02-22 Altek Corporation Battery security device
EA016079B1 (ru) * 2007-01-10 2012-01-30 Институто Ди Ричерке Ди Биолоджиа Молеколаре П. Анджелетти Спа Амидзамещенные индазолы в качестве ингибиторов поли(adp-рибоза)полимеразы (parp)
JP2008228154A (ja) * 2007-03-15 2008-09-25 Fujitsu Ltd 表示装置，および遠隔操作装置

Also Published As

Publication number Publication date
MX337421B (es) 2016-03-04
CA2711491A1 (en) 2009-07-16
NL300938I2 (nl) 2019-01-08
EP2240466A1 (en) 2010-10-20
CN101932572A (zh) 2010-12-29
RU2495035C2 (ru) 2013-10-10
EP2240466B1 (en) 2015-07-29
AU2009203598B2 (en) 2013-09-26
BRPI0906020A2 (pt) 2015-06-30
JP2011509252A (ja) 2011-03-24
MX2010006593A (es) 2010-12-21
AU2009203598A1 (en) 2009-07-16
ZA201003902B (en) 2011-02-23
RU2010133241A (ru) 2012-02-20
IL206201A0 (en) 2010-12-30
WO2009087381A1 (en) 2009-07-16
KR101653548B1 (ko) 2016-09-02
FR18C1020I1 (enExample) 2018-07-13
US8436185B2 (en) 2013-05-07
CN106008460B (zh) 2022-08-12
JP5989965B2 (ja) 2016-09-07
CN106008460A (zh) 2016-10-12
NZ586675A (en) 2012-04-27
CA2711491C (en) 2016-03-08
KR20100114021A (ko) 2010-10-22
IL206201A (en) 2014-07-31
ES2548131T3 (es) 2015-10-14
US20100286203A1 (en) 2010-11-11

Similar Documents

Publication Publication Date Title
ZA201003902B (en) Pharmaceutically acceptable salts of 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide
FIC20200051I1 (fi) Entrektinibi tai sen tautomeerit tai farmaseuttisesti hyväksyttävät suolat
LU92864I2 (fr) Cobicistat ou un de ses sels pharmaceutiquement acceptables
NL300998I2 (nl) Lusutrombopag of farmaceutisch aanvaardbare zouten of solvaten daarvan
CY2017042I1 (el) Ενωσεις πυρρολοπυριμιδινης ως αναστολεις cdk
RU2465270C3 (ru) Полиморфная форма 4-[3-(4-циклопропанкарбонилпиперазин-1-карбонил)-4-фторбензил]-2н-фталазин-1-она
BRPI0817537A2 (pt) 4-[3-(4-ciclopropanocarbonil-piperazina-i-carboni-,-fl uoro-benzil]-2h-ftalazin-1-ona
ITMI20061958A1 (it) Set di blocchi per la costruzione di giochi
EP2003722A4 (en) STACK CELL
BRPI0915714A2 (pt) forma cristalina de posaconazol
DK2021335T3 (da) Heterocykliske forbindelser som C-FMS-kinasehæmmere
BRPI0715617A2 (pt) Derivados do ácido fenoxifenilacético 4-substituído
PL2026747T3 (pl) Doustne kompozycje zapewniające polepszone usuwanie przebarwień nazębnych
BRPI0921596A2 (pt) Compostos de 4-[2-(2-fluorofenoximetil) fenil] piperidina
NL301214I2 (nl) Lasmiditan en farmaceutisch aanvaardbare zouten daarvan
CR10879A (es) Cyclized derivatives as eg-5 inhibitors
IL219997A0 (en) 4-[2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine salts
SMT201400053B (it) Forme farmaceutiche orali di bendamustina
SMT201300070B (it) Composti eterociclici di fenossimetile
JP2009543766A5 (ja) ｍＰＧＥｓ−１阻害剤としての２−アリールインドール誘導体
DK2049480T3 (da) 2-arylindolderivater som mPGES-1-hæmmere
PL2722046T3 (pl) Postać krystaliczna 1 2-((R)-2-metylopirolidyn-2-ylo)-1H-benzoimidazolo-4-karboksyamidu
DK2246477T3 (da) Spunspæl med dobbelt t-form
IL200959A0 (en) Liquid formulations of salts of 4-[2-(4-methylphenylfanyl)phenyl]piperidine
EP2222662A4 (en) INHIBITORS OF KYNURENINE AMINO TRANSFERASE